These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38802176)

  • 1. From use of omics to systems biology: Identifying therapeutic targets for amyotrophic lateral sclerosis.
    Castelli L; Vasta R; Allen SP; Waller R; Chiò A; Traynor BJ; Kirby J
    Int Rev Neurobiol; 2024; 176():209-268. PubMed ID: 38802176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis.
    Mitropoulos K; Katsila T; Patrinos GP; Pampalakis G
    OMICS; 2018 Jan; 22(1):52-64. PubMed ID: 29356625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further development of biomarkers in amyotrophic lateral sclerosis.
    Blasco H; Vourc'h P; Pradat PF; Gordon PH; Andres CR; Corcia P
    Expert Rev Mol Diagn; 2016 Aug; 16(8):853-68. PubMed ID: 27275785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common Factors in Neurodegeneration: A Meta-Study Revealing Shared Patterns on a Multi-Omics Scale.
    Ruffini N; Klingenberg S; Schweiger S; Gerber S
    Cells; 2020 Dec; 9(12):. PubMed ID: 33302607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 'Omics' of Amyotrophic Lateral Sclerosis.
    Caballero-Hernandez D; Toscano MG; Cejudo-Guillen M; Garcia-Martin ML; Lopez S; Franco JM; Quintana FJ; Roodveldt C; Pozo D
    Trends Mol Med; 2016 Jan; 22(1):53-67. PubMed ID: 26691296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The application of multi-omics and systems biology to identify therapeutic targets in chronic kidney disease.
    Cisek K; Krochmal M; Klein J; Mischak H
    Nephrol Dial Transplant; 2016 Dec; 31(12):2003-2011. PubMed ID: 26487673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omics Data and Their Integrative Analysis to Support Stratified Medicine in Neurodegenerative Diseases.
    La Cognata V; Morello G; Cavallaro S
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular insights and therapeutic targets in amyotrophic lateral sclerosis.
    Tripathi VB; Al-Chalabi A
    CNS Neurol Disord Drug Targets; 2008 Feb; 7(1):11-9. PubMed ID: 18289027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future.
    Wobst HJ; Mack KL; Brown DG; Brandon NJ; Shorter J
    Med Res Rev; 2020 Jul; 40(4):1352-1384. PubMed ID: 32043626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities.
    Soares P; Silva C; Chavarria D; Silva FSG; Oliveira PJ; Borges F
    Ageing Res Rev; 2023 Jan; 83():101790. PubMed ID: 36402404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A computational biology approach to identify potential protein biomarkers and drug targets for sporadic amyotrophic lateral sclerosis.
    Kumar R; Malik MZ; Thanaraj TA; Bagabir SA; Haque S; Tambuwala M; Haider S
    Cell Signal; 2023 Dec; 112():110915. PubMed ID: 37838312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Multi-Omics Approaches to Precision Medicine in Amyotrophic Lateral Sclerosis.
    Morello G; Salomone S; D'Agata V; Conforti FL; Cavallaro S
    Front Neurosci; 2020; 14():577755. PubMed ID: 33192262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
    Xu X; Shen D; Gao Y; Zhou Q; Ni Y; Meng H; Shi H; Le W; Chen S; Chen S
    Transl Neurodegener; 2021 Aug; 10(1):29. PubMed ID: 34372914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic and transcriptomic advances in amyotrophic lateral sclerosis.
    Rizzuti M; Sali L; Melzi V; Scarcella S; Costamagna G; Ottoboni L; Quetti L; Brambilla L; Papadimitriou D; Verde F; Ratti A; Ticozzi N; Comi GP; Corti S; Gagliardi D
    Ageing Res Rev; 2023 Dec; 92():102126. PubMed ID: 37972860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omics-based exploration and functional validation of neurotrophic factors and histamine as therapeutic targets in ALS.
    Volonté C; Morello G; Spampinato AG; Amadio S; Apolloni S; D'Agata V; Cavallaro S
    Ageing Res Rev; 2020 Sep; 62():101121. PubMed ID: 32653439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis.
    Thompson AG; Oeckl P; Feneberg E; Bowser R; Otto M; Fischer R; Kessler B; Turner MR
    Expert Rev Proteomics; 2021 Nov; 18(11):977-994. PubMed ID: 34758687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-modifying therapies in amyotrophic lateral sclerosis.
    Chiò A; Mazzini L; Mora G
    Neuropharmacology; 2020 May; 167():107986. PubMed ID: 32062193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic development in amyotrophic lateral sclerosis.
    Bucchia M; Ramirez A; Parente V; Simone C; Nizzardo M; Magri F; Dametti S; Corti S
    Clin Ther; 2015 Mar; 37(3):668-80. PubMed ID: 25666449
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.